期刊文献+

重症肌无力胸腺切除术的术前准备分析 被引量:2

PREOPERATIVE PREPARATION FOR MYASTHENIA GRAVIS PATIENTS UNDERGOING THYMECTOMY
暂未订购
导出
摘要 目的:探讨重症肌无力(MG)患者胸腺切除术的术前准备注意事项。方法:分析55例患者术前准备经过,包括抗胆碱酯酶药和皮质类固醇激素的应用,补钾及麻醉前用药等。比较了术前使用激素(激素组,n=20)和不用者(非激素组,n=35)术后呼吸恢复经过(肌无力危象的发生和因危象或呼吸恢复差而需呼吸支持)。结果:本组患者术前40%存在低钾;术前应用哌替啶不会造成呼吸抑制;术前使用激素与否对术后呼吸恢复无影响(P>005)。结论:MG患者易出现低钾,应予重视;哌替啶1mg·kg-1肌注作为经过充分准备的MG患者术前用药是安全的;本组病例中术前使用皮质类固醇激素并未能改善术后呼吸恢复经过。 Objective: To find the key points of preoperative preparation for myasthenia gravis (MG)patients undergoing thymectomy. Methods: To review the 55 MG patients′ preoperative preparation, including administration of cholinesterase inhibitor(CHEI), corticosteroid, potassium and preanesthetic medication. Compared the respiratory recovery process (incidence of respiratory support and myasthenic crisis respectively) between the patients received preoperative corticosteroid therapy (Group C,n=20) or not (Group NC,n=35). Results: In this series we observed, 40% of the patients were hypopotassemia preoperatively. Pethidine used as preanesthetic medication would not cause respiratory depression. There is no statistical difference between Group C and Group NC about the incidence of postoperative respiratory support and myasthenic crisis(P>0 05). Conclusions: Hypopotassemia should be carefully corrected preoperatively because of the high incidence(40%) of hypopotassemia in MG patients. Pethidine 1 mg·kg -1 administered intramuscularly is a safe preanesthetic medication for MG patients and preoperative corticosteroid could not improve postoperative respiratory recovery process in this series.
出处 《中山医科大学学报》 CSCD 1998年第4期303-306,共4页 Academic Journal of Sun Yat-sen University of Medical Sciences
关键词 重症肌无力 胸腺切除 术前用药 myasthenia gravis/surgery thymectomy/methods premedication
  • 相关文献

参考文献4

  • 1张蔚,国外医学.麻醉学与复苏分册,1993年,15卷,3期,175页
  • 2林桂芳,麻醉与内分泌,1990年
  • 3马君志,中华麻醉学杂志,1983年,3卷,4期,222页
  • 4刘锡民,内科学讲座,1983年,491页

同被引文献19

  • 1Agius MA,Richman DP,Fairclough RH,et al.Three forms ofimmune myasthenia[J].Ann N Y Acad Sci,2003,998:453-456.
  • 2Lindstrom JM,Seybold ME,Lennon VA,et al.Antibody to acetyl-choline receptor in myasthenia grads:Prevalence,clinical corre-lates,and diagnostic value[J].Neurology,1998,51(4):933.
  • 3Dan D, Bart P A, Novy J, et al. Double seronegative myasthenia gravis with antiphospholipid syndrome: a case report [J].J Med Case Rep, 2014,8(1):2.
  • 4Angelini C. Diagnosis and management of autoimmune myasthenia gravis [ J ]. Clin Drug Investig, 2011,31 ( 1 ) : 1-14.
  • 5Hill M. The neuromuscular junction disorders [J]. J Neurol Neurosurg Psychiatry, 2003,74(2) : 32-37.
  • 6Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis [J]. J Neurol Sci, 2004,217(2) : 131-133.
  • 7Murthy JM. Thymectomy in myasthenia gravis [J]. Neurology India,2009, 57(4): 363-365.
  • 8Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Mvasthenia Gravis Foundation of America [J]. Ann Thorac Surg, 2000,70 ( 1 ) : 327-334.
  • 9Meriggioli MN. Myasthenia gravis with anti-acetylcholine receptor antibodies [ J ]. Front Neurol Neurosci, 2009,26 : 94- 108.
  • 10Mandawat A, Kaminski HJ, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis [ J ]. Ann Neurol, 2010,68(6) :797-805.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部